A New Era in Oncology

Our
Pioneering Approach


We are a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer. We apply our ProTide technology to transform some of the most widely prescribed chemotherapy agents, nucleoside analogs, into more effective and safer medicines.

Learn more
helix
molecular structure

Our
ProTide Technology


We harness the power of phosphoramidate chemistry to develop next-generation chemotherapeutics designed to overcome the key cancer resistance mechanisms of existing nucleoside analogs.

Discover More

Our
Mission Statement


“To significantly improve the survival outcomes for patients by transforming chemotherapy and pioneering a new era in oncology”.

Hugh S. Griffith - Founder & CEO

Learn more
Hugh Griffith CEO

To Transform Chemotherapy and Pioneer a New Era in Oncology

Jigsaw pieces

Our
Leadership Team


Our highly experienced team has a successful track record of building global biopharmaceutical companies and developing new life-saving medicines for patients.

Read More

Our
Latest News


Edinburgh: September 2020

NuCana Announces Pricing of a Public Offering of American Depositary Shares

More News

Our
Upcoming Events


Edinburgh: August 2020

NuCana to Present Three Abstracts at the European Society for Medical Oncology (ESMO) Virtual Congress September 2020
September 19 - 21, 2020

Past Events

Our
Contact Details


Global Headquarters

3 Lochside Way, Edinburgh, EH12 9DT, UK

info@nucana.com

+ 44 131 357 1111

US Office

275 Grove Street, Newton, MA 02466, US

info@nucana.com

+1 617 663 5708

* These fields are required.